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Background. Human immunodeﬁciency virus (HIV) and human cytomegalovirus (HCMV) coinfections
have been shown to increase infant morbidity, mortality, and AIDS progression. In HIV-endemic regions, maternal
HIV-exposed but HIV-uninfected infants, which is the majority of children affected by HIV, also show poor growth
and increased morbidity. Although nutrition has been examined, the effects of HCMV infection have not been
evaluated. We studied the effects of HCMV infection on the growth, development, and health of maternally HIV-
exposed and unexposed infants in Zambia.
Methods. Infants were examined in a cohort recruited to a trial of micronutrient-fortiﬁed complementary
foods. HIV-infected mothers and infants had received perinatal antiretroviral therapy to prevent mother-to-child
HIV transmission. Growth, development, and morbidity were analyzed by linear regression analyses in relation to
maternal HIV exposure and HCMV infection, as screened by sera DNA for viremia at 6 months of age and by
antibody for infection at 18 months.
Results. All HCMV-seropositive infants had decreased length-for-age by 18 months compared with seronegative
infants (standard deviation [z]-score difference: 20.44 [95% conﬁdence interval {CI}, 2.72 to 2.17]; P 5 .002).
In HIV-exposed infants, those who were HCMV positive compared with those who were negative, also had reduced
head size (mean z-score difference: 20.72 [95% CI, 21.23 to 2.22]; P 5 .01) and lower psychomotor development
(Bayley test score difference: 24.1 [95% CI, 27.8 to 2.5]; P 5 .03). HIV-exposed, HCMV-viremic infants were more
commonly referred for hospital treatment than HCMV-negative infants. The effects of HCMV were unaffected by
micronutrient fortiﬁcation.
Conclusion. HCMV affects child growth, development, and morbidity of African infants, particularly in those
maternally exposed to HIV. HCMV is therefore a risk factor for child health in this region.
Human cytomegalovirus (HCMV) commonly infects
children, establishing a lifelong latent infection. It is
mainly a pathogen in an immunocompromised set-
ting, particularly for human immunodeﬁciency virus
(HIV)/AIDS and transplantation patients, where
HCMV can reactivate. HCMV is the main infectious
cause of mental retardation and neurodevelopmental
impairment in neonates; thisi n c l u d e sh e a r i n gl o s s ,
chieﬂy from congenital infection in utero [1–4]. In
transplantation patients, HCMV-associated pneumoni-
tis has a high mortality rate that is controlled primarily
with ganciclovir. Prior to antiretroviral therapy (ART)
in adult HIV/AIDS patients, HCMV was a major
Received 30 June 2011; accepted 7 October 2011.
a The members of the CIGNIS Study Group are detailed in the Acknowl-
edgments.
Correspondence: Ursula A. Gompels, PhD, Faculty of Infectious and Tropical
Diseases, London School of Hygiene and Tropical Medicine, University of London,
Keppel St, London WC1E 7HT, UK (ursula.gompels@lshtm.ac.uk).
Clinical Infectious Diseases 2012;54(3):434–42
 The Author 2011. Published by Oxford University Press on behalf of the
Infectious Diseases Society of America. All rights reserved. For Permissions, please
email:journals.permissions@oup.com. This is an Open Access article distributed
under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non--
commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.
DOI: 10.1093/cid/cir837
434 d CID 2012:54 (1 February) d HIV/AIDSopportunistic infection that correlated with retinitis, leading to
blindness as well as disseminated infections and in turn mor-
tality [5]. In childhood HIV, HCMV coinfection can be partic-
ularly severe; studies in the United States showed increased
neurological disease, AIDS progression, and mortality [6, 7]. In
HIV-endemic sub-Saharan Africa, pediatric ART is restricted
and HCMV complications are only beginning to be addressed;
even the extent of HCMV effects on the general child population
has not been established. In Kenyan infants, HIV infection was
associated with impaired control of HCMV replication [8].
In Zambia, autopsy studies of HIV-positive children who
died from respiratory disease identiﬁed HCMV as a frequent
infection, often together with tuberculosis [9, 10].
HCMV may also affect infants born to HIV-positive mothers,
even if the infants remain HIV-negative. HIV-positive mothers
can have reduced maternal passive immunity to protect their
infants against HCMV disease. This includes protective cytokines
or antibodies, immunoglobulin G (IgG) transcytosed across
the placenta in utero to the fetus, or immunoglobulin A (IgA)
secreted in breast milk to protect against gut infection in the
newborn. Moreover, immunosuppression in the HIV-positive
mother can lead to increased HCMV levels due to reactivation
or secondary infection. Little is known about how these effects
impact childhood HCMV in HIV-endemic African populations.
The number of children who are maternally HIV exposed
but not infected is increasing due to the epidemic spread of
HIV and also ART introduction to decrease mother-to-child
HIV transmission.
We previously reported that in Zambia, where HIV is en-
demic, children are exposed to a complex collection of HCMV
strains, as exists elsewhere, but also show increased prevalence
of higher loads transmitted from HIV-positive mothers [10].
HIV-exposed infants do not grow as well as unexposed infants,
have increased morbidity, and are particularly vulnerable when
they transition from breastfeeding [11, 12]. Here we report the
effects of HCMV infection on growth, development, and health
of HIV-exposed and unexposed infants in Zambia who were
r e c r u i t e dt oad o u b l e - b l i n d ,r a n d o m i z e dc o n t r o l l e dt r i a lo f
micronutrient-fortiﬁed infant foods [13]. The results identify
HCMV as a pathogen associated with poor development
including evidence of increased morbidity, irrespective of diet.
METHODS
Study Design, Population, and Recruitment
A total of 811 infants were recruited for a trial of micronutrient-
fortiﬁed complementary foods. The trial was conducted in
Chilenje at the University Teaching Hospital (UTH), Lusaka,
Zambia, from October 2005 to July 2009, registered as
ISRCTN37460449 (www.controlled-trials.com/mrct), with 77%
completionratesas described [13].Theinfantswererepresentative
of the region, as mothers were recruited during their infant’s
standard care checks for weighing or vaccinations, and coverage
for these services is high in Lusaka.
Follow-up, Anthropometry, and Sera Collection
Anthropometry and standard deviation z scores were calculated
using World Health Organization (WHO) growth reference
data, as described [13]. Stunting was recorded as length/age
z ,22. Venous blood was collected in plain vacutainers at age
6 months and 18 months; sera were separated within 2 hours,
aliquoted, and stored at 280C.
HIV Antibody Testing
Serum samples at 18 months were tested for HIV antibodies
using Determine HIV 1/2 (Inverness Medical). Negative results
were recorded; positive results were further tested using Unigold
HIV 1/2 (Trinity Biotech). If a negative, discordant result was
shown, a third test, SD-Bioline HIV 1/2 (Standard Diagnostics),
was used.
Human Cytomegalovirus Antibody and DNA Testing
The ETI-CYTOK-G PLUS enzyme-linked immunosorbentassay
kit (DiaSorin)for detectionofanti-HCMVIgG inhuman serum
was used in accordance with the manufacturer’s instructions.
Standard curves were plotted; control sera standards were
used to interpolate sample IgG titers with positive antibody
titers read above a cutoff of 0.4 IU/mL. Qualitative and quan-
titative polymerase chain reaction (PCR) was performed on
DNA extracted from 200 lL of sera using the QIAamp DNA
Blood Mini Kit (Qiagen). PCR was used to amplify HCMV
glycoprotein gB (UL55), as described previously [10], with base-
line and high-load cutoff sensitivities of 50 and 1000 copies/mL
of sera, respectively.
Morbidity Assessments
The clinical ofﬁcer (J. S.) examined children during scheduled
or voluntary visits, with diagnoses and treatment given based
on WHO guidelines for Integrated Management of Childhood
Illness [13]. Prescriptions for antibiotics or antimalarials were
provided at the study clinic. Hospital referrals were deﬁned
as those made to the local tertiary facility (UTH), with severe
symptoms (inability to drink or breastfeed, severe vomiting,
convulsions, respiratory distress, loss of consciousness, or severe
lethargy), for surgery, or with an illness requiring consultation
with a specialist.
Bayley Testing of Development
Child development tests were administered by 2 trained psy-
chologists using Bayley scales of infant development (BSID II).
The mental development index (MDI) and psychomotor de-
velopment index (PDI) were used as standardized in the United
States [14] and age-normalized to a population mean of 100
and SD of 15. Some items were adapted to local settings (doll
HIV/AIDS d CID 2012:54 (1 February) d 435appearance or house pictures) while keeping underlying
constructs. The test was translated to local languages (Bemba
and Nyanja). If a child was sick at the time of assessment, the
mother was asked to bring the child back 1–2 weeks after re-
covery. For logistical reasons, testing was conducted on a subset,
including all with HIV-positive mothers and alternate infants
with HIV-negative mothers.
Statistical Analysis
Growth and reported illness werec o m p a r e db e t w e e ni n f a n t s
with and without HCMV using v
2 tests. The impact of HCMV
infection on length-for-age (LAZ), weight-for-age (WAZ), head
circumference-for-age (HCZ), and arm circumference-for-age
(ACZ) z scores at 18 months was analyzed as a continuous
variable using linear regression and 95% conﬁdence intervals
(CIs) for regression coefﬁcients. The impact on incidence of
severe morbidity, deﬁned as hospital referral or death, was es-
timated using rate ratios (RRs) and 95% CIs obtained using
random-effects Poisson regression to account for repeated re-
ferrals among infants. Any planned surgeries were excluded
(5 circumcisions, 4 hernias, and 4 other congenital abnormal-
ities). It was decided a priori to perform analyses stratiﬁed
by maternal HIV status; this excluded the 70 infants of HIV-
unknown women. Maternal education, socioeconomic status
(SES), and diet intervention arm were determined a priori as
potential confounders. Adjustments were made for these
a priori confounders as well as for breastfeeding duration
(shorter or longer than 6 months), which was determined to
be associated with HCMV infection in risk factor analyses.
SES was measured by an asset index, as described previously
[13]. Interobserver reliability of the Bayley test was obtained in
663 testing sessions during which the same child was scored by
the2psychologists.Theintraclasscorrelationcoefﬁcient(ICC)of
the scoreswascalculatedusing1-wayanalysisof variance. A good
agreement between scorers was found for both MDI
(ICC 5 0.91 [95% CI, .89–.92]) and PDI (ICC 5 0.91 [95% CI,
.90–.92]). MDI and PDI scores were analyzed as continuous
variables and checked for normality on a normal probability plot.
The association of Bayley test scores and HCMV seropositive
antibody at 18 months was examined using linear regression
with subsequent adjustment for SES, mother’s education, diet
intervention arm, and breastfeeding duration. A 2-sided P value
#.05 was considered statistically signiﬁcant. Stata software
(version 11.1, StataCorp) was used in all analyses.
Multiple Imputation Analyses
Among the 811 children enrolled in the study, 561 (69%) were
available for HCMV DNA at 6 months, 430 (53%) for HMCV
DNA at 18 months, and 460 (57%) for HCMV antibody at
18 months. Any missing data were mainly due to limitations on
the infant serum sample volume after the large number of
previous metabolic assays, which were used to interpret the
primary outcome analyses, as described [13]. Ninety samples
were missing due to participant withdrawal from the study. In
order to account for infants who were missing data, we used
multiple imputations with chained equations methods using
Stata software. Factors predictive of missing data (small child),
risk factors for HCMV (mother’s education, SES, breastfeeding
duration, and maternal HIV status), and the micronutrient diet
intervention arm were used to impute 10 data sets. All continuous
variables used in the imputation were normally distributed; SES
and mother’s education were treated as ordered categorical
variables. In addition to the main analyses of observed data,
complete analyses were conducted with all imputed data.
Ethics
The study received approval from the ethics committees of
the University of Zambia and the London School of Hygiene
and Tropical Medicine. The funding source, the Bill and
Melinda Gates Foundation, was not involved in the study or
its interpretation.
RESULTS
Growth Effects
In order to analyze the effects of HCMV on growth, 2 measure-
ments were made: HCMV viremia at recruitment (age 6 months;
sera DNA) and HCMV infection at the end of the study
(age 18 months; sera antibody). The antibody was used to
measure infection occurring in the cohort by 18 months; the
DNA assay detects HCMV viremia on recruitment at 6 months,
either primary or earlier, uncontrolled infections.
Among all children there was no signiﬁcant effect of HCMV
viremia on growth from age 6 months to 18 months. However,
when the population was stratiﬁed for maternal HIV exposure,
there were signiﬁcant associations, but in opposing directions
(Table1). Among HIV-exposed childrenwithHCMVviremia at
6 months, there was reduced LAZ (P 5 .04), with evidence for
interaction of HCMV viremia with maternal HIV on LAZ (in-
teraction, P 5 .007). Similar but nonsigniﬁcant directions were
seen for WAZ and HCZ. With multiple imputations, the effect
onLAZ in HIV-exposedinfants remained (regression coefﬁcient
of 20.40 to 20.28; interaction, P 5 .07). When HIV-positive
childrenwere removed from the analysis,thereduced LAZ effect
remained for the maternally HIV-exposed uninfected infants.
Incontrast, amongchildren ofHIV-negative mothers, HCMV
viremia at 6 months was associated with increased LAZ and
HCZ. Effects of HCMV viremia in all infants were independent
of nutrition, either micronutrient intervention or breastfeeding
duration, as adjustments did not alter the associations. Ad-
justment for hemoglobin had no effect (data not shown).
Next, the effects of HCMV infection on growth by 18 months
(sera antibody) were analyzed. HCMV infection affected LAZ,
436 d CID 2012:54 (1 February) d HIV/AIDSwith reduced measures in all children (Table 2). The effects
remained after adjusting for SES, education, breastfeeding du-
ration, and diet treatment arm (adjusted regression co-
efﬁcient, 20.33 [95% CI, 2.60 to 2.06]; P 5 .01; adjusted
regression coefﬁcient was 0.04 after Bonferroni correction). The
results were similar after multiple imputations for missing data
(data not shown). There was 3-fold more stunting (LAZ ,22)
associated with HCMV infection in maternally HIV-exposed
infants and unexposed infants (Figure 1). The other anthro-
pometric measures were also negatively associated with HCMV
infection by 18 months; only results for HCZ were statistically
signiﬁcant, with the greatest effects among HIV-exposed chil-
dren (regression coefﬁcient, 20.71; interaction P 5 .02). This
HCZ effect was similar after multiple imputations, although sig-
niﬁcance was borderline (regression coefﬁcient, 20.57; P 5 .09).
Because maternal HIV exposure has been shown to increase
the prevalence of congenital HCMV infection [7, 15], and this
may affect head size, an additional adjustment was made for
viremia at 6 months, and this would include congenital infec-
tion. Adjustment strengthens the association (regression
coefﬁcient, 20.80 [95% CI, 21.40 to 2.20]), suggesting that
overall HCMV infection from 6 to 18 months is a main effect.
Morbidity Effects
Table 3 shows effects of HCMV viremia and infection on
infant hospitalization or death. Although no associations
were statistically signiﬁcant, the directions were consistent
with HCMV viremia at recruitment (age 6 months), with fewer
hospitalizations among HIV-unexposed infants and increased
hospitalizations for HIV-exposed or HIV-infected infants. The
increased hospitalizations were concentrated in infants co-
infected with HIV and HCMV. Similar results are shown using
a higher threshold for copy number of HCMV DNA in sera of
1000 copies/mL and after further sensitivity analyses (P 5 .09).
Development Effects
Mental and psychomotor development was assessed using Bayley
tests. HIV-exposed infants with HCMV viremia at 6 months
showed a borderline signiﬁcance for decreased psychomotor
skills (PDI) (Table 4). By 18 months, HIV-exposed infants
with HCMV infection detected by antibody had signiﬁcantly
Table 1. Effect of Human Cytomegalovirus Viremia (Sera DNA) at 6 Months on Anthropometric z Scores at 18 Months
Mean (SD)
Unadjusted
Regression
Coefﬁcient (95% CI) P Value
Adjusted
Regression
Coefﬁcient
a (95% CI) P Value
Adjusted
Regression
Coefﬁcient
b (95% CI) P Value
HCMV
Negative
HCMV
Positive
All children n 5 336 n 5 226
Length 21.05 (1.17) 21.03 (1.07) 0.02 (2.19 to .23) .87 0.05 (2.15 to .25) .61 0.06 (2.14 to .26) .55
Weight 20.50 (1.23) 20.50 (1.14) 0.00 (2.23 to .22) .99 0.03 (2.18 to .25) .77 0.04 (2.18 to .25) .72
Head
circumference
0.57 (0.97) 0.61 (1.06) 0.05 (2.14 to .23) .64 0.08 (2.11 to .26) .40 0.10 (2.09 to .28) .30
Arm
circumference
0.20 (1.15) 0.01 (1.06) 20.20 (2.41 to .01) .07 20.17 (2.37 to .04) .11 20.16 (2.36 to .05) .13
Maternal HIV
negative
n 5 241 n 5 152
Length 21.06 (1.19) 20.81 (1.00) 0.25 (.00–.51) .06 0.24 (.00 to .48) .05 0.24 (.00 to .48) .05
Weight 20.48 (1.25) 20.28 (1.07) 0.19 (–.08 to .47) .17 0.19 (–.07 to .45) .16 0.19 (2.07 to .46) .15
Head
circumference
0.62 (1.00) 0.84 (1.01) 0.22 (2.01 to .45) .06 0.23 (.00 to .46) .05 0.24 (.01 to .46) .04
Arm
circumference
0.27 (1.13) 0.16 (0.95) 20.11 (2.37 to .15) .40 20.10 (2.35 to .15) .43 20.10 (2.35 to .15) .43
Maternal HIV
positive
n 5 65 n 5 55
Length 21.09 (1.07) 21.54 (1.14) 20.45 (2.89 to –.02) .04 20.40 (2.80 to .01) .05 20.40 (2.80 to .00) .05
Weight 20.58 (1.16) 20.94 (1.30) 20.36 (2.82 to .10) .13 20.31 (2.75 to .13) .16 20.32 (2.76 to .13) .16
Head
circumference
0.42 (0.91) 0.25 (1.09) 20.17 (2.56 to .22) .40 20.13 (2.51 to .25) .50 20.12 (2.50 to .26) .54
Arm
circumference
0.01 (1.28) 20.36 (1.27) 20.36 (2.80 to .07) .10 20.33 (2.75 to .09) .13 20.33 (2.75 to .09) .12
P values for interaction HCMV viremia with maternal HIV: length-for-age 5 .007, weight-for-age 5 .05, head circumference-for-age 5 .11, and arm circumference-
for-age 5 .35. Infants of women with unknown HIV status were excluded from the stratiﬁed analyses.
Abbreviations: CI, conﬁdence interval; HCMV, human cytomegalovirus; HIV, human immunodeﬁciency virus; SD, standard deviation.
a Adjusted for maternal socioeconomic status and education.
b Additionally adjusted for diet treatment arm and breastfeeding duration.
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Mean (SD)
Unadjusted Mean
Difference (95% CI) P Value
Adjusted Mean
Difference
a (95% CI) P Value
Adjusted Mean
Difference
b (95% CI) P Value HCMV Negative HCMV Positive
All children n 5 76 n 5 384
Length 20.72 (1.07) 21.17 (1.11) 20.44 (–.72 to 2.17) .002 20.31 (–.58 to 2.05) .02 20.33 (2.60 to 2.06) .01
Weight 20.34 (1.10) 20.64 (1.15) 20.30 (–.58 to 2.01) .04 20.15 (2.42 to .13) .29 20.17 (2.45 to .11) .22
Head circumference 0.79 (1.00) 0.49 (0.99) 20.31 (–.55 to 2.06) .01 20.21 (2.45 to .04) .10 20.25 (2.49 to .00) .05
Arm circumference 0.05 (1.14) 0.03 (1.06) 20.01 (2.28 to .25) .92 0.11 (2.15 to .38) .40 0.06 (2.21 to .33) .65
Maternal HIV negative n 5 49 n 5 263
Length 20.63 (1.06) 21.13 (1.13) 20.49 (–.83 to 2.15) .01 20.38 (–.71 to –.06) .02 20.38 (–.71 to –.06) .02
Weight 20.26 (1.05) 20.59 (1.15) 20.33 (2.68 to .03) .07 20.19 (2.53 to .16) .29 2.19 (2.53 to .16) .29
Head circumference 0.74 (0.95) 0.59 (1.00) 20.15 (2.46 to .15) .33 20.05 (2.35 to .26) .77 20.04 (2.34 to .27) .82
Arm circumference 0.18 (1.07) 0.13 (1.00) 20.06 (2.39 to .28) .74 0.08 (2.25 to .40) .65 0.08 (2.25 to .42) .62
Maternal HIV positive n 5 19 n 5 86
Length 20.85 (1.11) 21.35 (1.10) 20.49 (21.05 to .06) .08 20.29 (2.82 to .23) .27 20.29 (2.83 to .25) .30
Weight 20.56 (1.20) 20.79 (1.22) 20.23 (2.81 to .34) .43 20.02 (2.57 to .53) .93 20.08 (2.65 to .49) .78
Head circumference 0.95 (1.19) 0.25 (0.98) 20.71 (21.21 to 2.21) .01 20.60 (21.08 to 2.12) .02 20.72 (21.23 to 2.22) .01
Arm circumference 20.23 (1.38) 20.21 (1.23) 0.02 (2.52 to .56) .93 0.17 (2.35 to .69) .52 0.07 (2.48 to .62) .80
P values for interaction HCMV antibody with maternal HIV: length-for-age 5 .76, weight-for-age 5 .76, head circumference-for-age 5 .02, and arm circumference-for-age 5 .97. Infants of women with unknown HIV
status were excluded from the stratiﬁed analyses.
Abbreviations: CI, conﬁdence interval; HCMV, human cytomegalovirus; HIV, human immunodeﬁciency virus; SD, standard deviation.
a Adjusted for maternal socioeconomic status and education.
b Additionally adjusted for diet treatment arm and breastfeeding duration.
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Slower PDI after adjustment for SES, education, breastfeeding
duration, and diet intervention (regression coefﬁcient, 24.1
[95%CI,27.8 to 2.5];P 5 .03)(Table 5). HCMVdidnot affect
PDI in HIV-unexposed infants or mental development in either
subgroup.
DISCUSSION
The results show that HCMV is a widespread pathogen that
affects healthy growth and development of infants in Zambia.
In the maternally HIV-exposed infants, HCMV infection was
also associated with increased prevalence of stunting, reduced
head size, and decreased psychomotor development. Previous
analyses of this cohort showed that reduced growth in the HIV-
exposed infants was unaffected by micronutrient fortiﬁcation
but was affected by socioeconomic factors [13, 16]. The effects
of HCMV on growth were also inﬂuenced by socioeconomic
factors; however, the effects still existed after adjustments were
made for socioeconomic factors, education level, breastfeeding
duration, and diet. In Zambia we showed that HCMV infections
occurred earlier, that is, during infancy, and were more preva-
lent (83% IgG seropositive in this cohort) than in many other
geographic regions. Therefore, effects of HCMV on growth
could affect the majority of the infant population. Moreover,
growth effects at such an early age have been linked with life-
time risks of adult chronic disease and thus HCMV infection is
a general public health concern [17]. In the United States,
children studied from age 6 years, showed reduced growth as-
sociated with increased infectious burden, including HCMV
(30%–50% seropositive at outset). This resulted in health
disparities that persisted to middle age [18, 19].
HIV-unexposed infants with HCMV viremia at 6 months had
higher length and head circumference z scores, whereas among
maternally HIV-exposed infants, HCMV viremia was associated
with lower z scores. This suggests that HIV-uninfected mothers,
but not infected, provide some protective maternal immu-
nity, permitting infants to tolerate HCMV infection. In the
HIV-unexposed infants, HCMV may provide beneﬁcial im-
mune stimulation at this age, possibly contributing to the
Figure 1. Human cytomegalovirus (HCMV) seroprevalence correlates
with stunting at 18 months. Stunting (length/age z ,22) prevalence at
18 months is tripled in HCMV-seropositive infants. Significance is by
Pearson v
2:
aHuman immunodeficiency virus (HIV)–unexposed, P 5 .037;
bHIV-exposed, P 5 .071.
Table 3. Effect of Human Cytomegalovirus Viremia at 6 Months (Sera DNA) on Hospitalization
No./Person-Years
(Rate per 100 py)
Unadjusted RR
(95% CI) P Value
Adjusted RR
(95% CI)
a P Value
Adjusted RR
(95% CI)
b P Value HCMV Negative HCMV Positive
Standard threshold (50 copies/mL)
All children 61/288.5 (21.1) 43/204.6 (21.0) 1.00 (.65–1.53) ..99 1.04 (.68–1.59) .86 1.04 (.68–1.59) .85
Maternal HIV
Negative 44/202.4 (21.7) 21/134.2 (15.7) 0.72 (.41–1.25) .24 0.75 (.43–1.30) .31 0.74 (.43–1.29) .29
Positive 15/59.9 (25.0) 19/52.0 (36.5) 1.49 (.70–3.16) .30 1.62 (.77–3.43) .21 1.53 (.72–3.27) .27
Child HIV
Negative 11/50.3 (21.9) 7/43.1 (16.2) 0.76 (.29–1.96) .57 0.90 (.34–2.36) .83 0.96 (.36–2.57) .94
Positive 1/4.5 (22.4) 5/6.3 (79.9) 3.56 (.41–.80) .25 3.11 (.35–27.40) .31 5.08 (.55–47.30) .15
High threshold (.1000 copies/mL)
All children 61/288.5 (21.1) 6/31.0 (19.4) 0.93 (.38–2.31) .88 0.81 (.32–2.03) .65 0.86 (.34–2.18) .75
Maternal HIV
Negative 44/202.4 (21.7) 2/18.5 (10.8) 0.49 (.11–2.16) .35 0.47 (.10–2.12) .33 0.48 (.11–2.12) .33
Positive 15/59.9 (25.0) 4/11.5 (34.8) 1.48 (.43–5.13) .54 1.06 (.30–3.80) .93 1.28 (.36–4.54) .70
Abbreviations: CI, conﬁdence interval; HCMV, human cytomegalovirus; HIV, human immunodeﬁciency virus; py, person-years; RR, rate ratio.
a Adjusted for mother’s socioeconomic status and education.
b Additionally adjusted for breastfeeding duration (,6m o n t h s / $6 months) and diet treatment arm. Maternal HIV-exposure interaction with HCMV in a fully
adjusted model has a P value 5 .10.
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similar examples with other sequential infections; for example,
prior inﬂuenza infection affects outcome for subsequent re-
spiratory syncytial virus infection [20]. HCMV encodes
a number of immunomodulatory proteins that favor virus
persistence, but these proteins may also affect responses to
other infections and host survival [21–23]. However, even if
beneﬁcial in the short term, long-term HCMV immune stim-
ulation during infancy can be detrimental by driving early
immune senescence [24]. In West Africa, Malawi, and Gambia,
HCMV-infected infants had expanded HCMV-speciﬁc T lym-
phocytes with markers of aged anergic cells, which have been
previously identiﬁed in elderly European populations where
HCMV is acquired later [25, 26]. HCMV immune senescence
may compromise the ability to respond to new infections
during infancy in Africa, as suggested for the elderly in Europe
[24–26]. Therefore, increased overall burden of all infections
may affect healthy growth. This is supported by the 18-month
HCMV antibody data, which shows that when overall HCMV
infection is considered at times when maternal immunity
wanes, there is a negative effect on growth.
HCMV may also directly affect growth and development,
depending on the route of infection. HCMV frequently reactivates
in HCMV IgG-positive mothers during lactation, and the virus
Table 5. Effect of Human Cytomegalovirus Infection (Antibody) on Development at 18 Months
Mean (SD)
Unadjusted Regression
Coefﬁcient
a (95% CI) P Value
Adjusted Regression
Coefﬁcient
b (95% CI) P Value HCMV Negative HCMV Positive
All children n 5 48 n 5 239
MDI 89.2 (7.3) 88.8 (7.8) 20.4 (22.8 to 2.0) .73 20.1 (22.7 to 2.5) .97
PDI 92.2 (4.3) 90.4 (6.2) 21.8 (23.6 to .0) .05 22.0 (24.0 to .0) .05
Maternal HIV negative n 5 22 n 5 121
MDI 90.9 (6.6) 88.9 (8.2) 22.0 (25.7 to 1.7) .28 20.5 (24.2 to 3.3) .79
PDI 92.5 (4.4) 90.8 (6.3) 21.7 (24.5 to 1.1) .22 21.0 (23.8 to 1.8) .48
Maternal HIV positive n 5 19 n 5 86
MDI 87.5 (6.7) 87.8 (7.1) 0.3 (–3.2 to 3.8) .86 0.8 (-3.4 to 5.0) .71
PDI 92.1 (4.1) 89.2 (6.5) 22.8 (25.9 to .2) .07 24.1 (27.8 to 2.5) .03
P values for interaction between human cytomegalovirus exposure and maternal human immunodeﬁciency virus on mental development index 5 0.12, on
psychomotor development index 5 0.13.
Abbreviations: CI, conﬁdence interval; HCMV, human cytomegalovirus; HIV, human immunodeﬁciency virus; MDI, mental development index; PDI, psychomotor
development index; SD, standard deviation.
a Mean difference.
b Adjusted for socioeconomic status, mother’s education, diet intervention arm, and breastfeeding duration.
Table 4. Effect of Human Cytomegalovirus Viremia at 6 Months (Sera DNA) on Development at 18 Months
Mean (SD)
Unadjusted Regression
Coefﬁcient
a (95% CI) P Value
Adjusted Regression
Coefﬁcient
b (95% CI) P Value HCMV Negative HCMV Positive
All children n 5 155 n 5 121
MDI 89.2 (7.8) 89.2 (7.9) 0.0 (21.9 to 1.8) .97 20.1 (21.8 to 1.9) .93
PDI 91.0 (5.3) 90.4 (7.0) 20.6 (22.0 to .9) .46 20.7 (22.1 to .8) .35
Maternal HIV negative n 5 78 n 5 57
MDI 89.3 (7.9) 90.6 (6.9) 1.3 (21.3 to 3.9) .32 1.0 (21.6 to 3.6) .45
PDI 91.1 (5.2) 91.7 (5.9) 0.6 (21.3 to 2.5) .53 0.2 (21.7 to 2.2) .82
Maternal HIV positive n 5 55 n 5 49
MDI 88.0 (6.9) 87.4 (8.9) 20.6 (23.7 to 2.4) .68 20.6 (23.8 to 2.6) .73
PDI 90.9 (5.7) 88.6 (8.2) 22.3 (25.0 to .4) .09 22.5 (25.4 to .3) .08
P values for interaction between human cytomegalovirus viremia and maternal human immunodeﬁciency virus on mental development index = 0.03, on
psychomotor development index 5 0.07.
Abbreviations: CI, conﬁdence interval; HCMV, human cytomegalovirus; HIV, human immunodeﬁciency virus; MDI, mental development index; PDI, psychomotor
development index; SD, standard deviation.
a Mean difference.
b Adjusted for socioeconomic status, mother’s education, diet intervention arm, and breastfeeding duration.
440 d CID 2012:54 (1 February) d HIV/AIDSis detectable in milk whey. Furthermore, HCMV is a pathogen
of the gastrointestinal tract of HIV/AIDS patients and so may
alter nutrient absorption, and can invade the central nervous
system, possibly affecting development [3, 4, 27, 28]. HCMV
infection acquired in utero can cause neurological disease,
while later postnatal infections, primarily via breast milk, are
generally asymptomatic [5]. In utero infection may account for
HCMV effects on reduced head size and psychomotor de-
velopment in HIV-exposed infants because adjustments for
breastfeeding increased the effect. However, in separate analy-
ses, we showed that the major route for infection in this cohort
is via breastfeeding and that its duration over age 6 months is
a risk factor, particularly for HIV-exposed infants. Studies in
Europe of preterm births show symptomatic HCMV infection
acquired via breast milk is associated with a growth disadvantage
[29, 30]. High HCMV load and prolonged excretion in breast
milk are risk factors for acquisition [27]; both factors were
apparent for this HIV-exposed Zambian cohort.
Maternal HIV exposure increased some adverse effects of
HCMV. Our previous analyses indicated that maternal HIV
exposure led to a greater prevalence of high-load viremic infant
HCMV infections [10]. High-load HCMV viremia can correlate
withsymptomaticinfection[4,31,32].StudiesinKenyaofHIV-
positive mother/child pairs showed that detection of maternal
HCMV plasma DNA was associated with infant mortality [33].
In our Zambian cohort, there was some evidence of increased
hospitalization with HCMV viremia in the HIV-infected chil-
dren, but this was not signiﬁcant with maternal HIV exposure.
Therefore, by affecting other diseases, the effects of HCMV on
growth and development could be partially indirect; the effects
appear to be a combination of direct and indirect causes.
A limitation of our study was that the maternal CD4 count or
HCMV status was not available and we could not determine
the effects of HIV on maternal immunity or HCMV. Study
strengths include analyses of HCMV effects in infants using both
6-monthDNA for viremia and 18-month antibody for infection,
with comparisons between maternally HIV-exposed and HIV-
unexposed infants, controls for major confounding factors, and
a large population-based study, the ﬁrst in this region.
What may limit the effects of HCMV on infant growth and
development in this region? Diagnostics for symptomatic con-
genital infections and their treatment with ganciclovir or its
derivatives may be appropriate [34, 35]. Recent evidence shows
that high-avidity HCMV IgG can cross the placenta and con-
tribute to viral replication control [36]. This is an indication
that hyperimmune globulin could also limit placental infection
[35], and so improving maternal immunity could limit infec-
tion. In France, ART of HIV-positive women decreased HCMV
congenital infection [37]. For HIV-positive mothers, limiting
breastfeeding duration over 6 months could reduce infant
HCMVinfection;however,furtherstudyisrequiredtoassessthe
effects. In Zambia, HIV-positive women with advanced HIV/
AIDS improved infant survival by decreasing breastfeeding,
while those with less advanced HIV/AIDS improved survival of
HIV-positive infants by increasing breastfeeding duration to
longer than 4 months [38, 39]. Because HCMV is frequently
secreted in urine, improved hygiene could limit horizontal
transmission. Preliminary analyses showed lower HCMV infant
infection with the presence of private indoor toilets compared
with outdoor toilets. Ultimately, HCMV vaccination could
control new infections or reduce viremia in those already in-
fected. Early trials of a subunit vaccine show promise [40, 41].
In conclusion, HCMV infection in Zambia resulted in poor
growth and development of maternally HIV-exposed infants and
poor growth of HIV-unexposed children. Other African countries
also have high HCMV childhood infection and endemic HIV.
Therefore, efforts to improve child health will need to consider
HCMV, particularly for effects on growth and development.
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